Health Care [ 4/12 ] | Health Care Equipment & Supplies [ 43/72 ]
NASDAQ | Common Stock
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide.
Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; and ClearGuard HD, that maintains hemodialysis catheters.
The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options.
It offers infusion pumps under the Plum 360 brand; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; professional services; critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems.
The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities.
ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 7, 24 | 0.96 Decreased by -44.83% | 0.82 Increased by +17.07% |
| Feb 27, 24 | 1.57 Decreased by -1.88% | 1.19 Increased by +31.93% |
| Nov 6, 23 | 1.57 Decreased by -10.29% | 1.39 Increased by +12.95% |
| Aug 7, 23 | 1.88 Increased by +37.23% | 1.60 Increased by +17.50% |
| May 8, 23 | 1.74 Decreased by -4.40% | 1.43 Increased by +21.68% |
| Feb 27, 23 | 1.60 Decreased by -12.09% | 1.56 Increased by +2.56% |
| Nov 7, 22 | 1.75 Decreased by -15.46% | 1.46 Increased by +19.86% |
| Aug 8, 22 | 1.37 Decreased by -27.13% | 1.66 Decreased by -17.47% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 553.31 M Decreased by -7.45% | 7.24 M Increased by +154.80% | Increased by +1.31% Increased by +159.21% |
| Jun 30, 23 | 549.31 M Decreased by -2.08% | -9.93 M Decreased by -32.91% | Decreased by -1.81% Decreased by -35.74% |
| Mar 31, 23 | 568.65 M Increased by +4.70% | -9.81 M Increased by +74.23% | Decreased by -1.73% Increased by +75.38% |
| Dec 31, 22 | 578.01 M Increased by +69.74% | -15.54 M Decreased by -177.97% | Decreased by -2.69% Decreased by -145.94% |
| Sep 30, 22 | 597.86 M Increased by +77.90% | -13.21 M Decreased by -142.50% | Decreased by -2.21% Decreased by -123.89% |
| Jun 30, 22 | 561.00 M Increased by +74.40% | -7.47 M Decreased by -126.32% | Decreased by -1.33% Decreased by -115.09% |
| Mar 31, 22 | 543.12 M Increased by +70.77% | -38.07 M Decreased by -260.41% | Decreased by -7.01% Decreased by -193.94% |
| Dec 31, 21 | 340.52 M Increased by +6.26% | 19.93 M Decreased by -23.78% | Increased by +5.85% Decreased by -28.27% |